Movement Disorders Clinical Studies

Various clinical studies are currently enrolling patients with Parkinson Disease/Parkinsonism, Dystonia, Tourette Syndrome or Tics, Huntington Disease, Tremor and other types of movement disorders. If you are interested in participating in clinical studies in our division, please contact the research coordinator for each study.

Control Participants

Control subjects without movement disorders are needed for various studies. if you are interested in being a control participant in our studies, please contact the appropriate contact person noted below for eligibility.

Parkinson Disease

A Phase 3 double-blind placebo-controlled parallel group study of isradipine as a disease modifying agent in subjects with early Parkinson disease (STEADY-PD III Study) (more details) Brad Racette, MD Karen McDonell
314-747-0514
Exercise and Parkinson’s: Comparing Interventions and Exploring Neural Mechanisms (more details) Gammon Earhart, PT, PhD Martha Hessler
314-286-1478
Efficacy and Safety of ADS-5102 (amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia in Parkinson’s Disease Patients (EASE LID Study). (more details) Susan Criswell Karen McDonell
314-747-0514
Feasibility and Optimization of a Cognitive Intervention for Parkinson disease. (more details) Erin Foster Tasha Doty
314-362-7160
A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Effficacy of Oral Istradefylline 20 and 40 mg/day as Treatment for Subjects with Moderate to Severe Parkinson’s Disease.(more details) Susan Criswell, MD Karen McDonell
314-747-0514
Chronic Disease Self-Management for Parkinson Disease (CDSM4PD) (more details) Erin Foster Tasha Doty
314-362-7160
Use of PIB PET imaging to evaluate dementia subtypes in patients with Parkinson Disease
(more details)
Joel Perlmutter Barbara Merz
314-362-0420
Mapping Mood in the Subthalamic Nucleus in PD (more details) Tamara Hershey Samantha Blankenship
314-362-6514
Effects of Dopamine on Functional Connectivity in Parkinson Disease (more details) Joel Perlmutter Barbara Merz
314-362-0420
Molecular Genetic Studies of Parkinsonism (more details) Joel Perlmutter Anja Pogarcic
314-362-3483

Huntington’s Disease

Study Title Principal Investigator Contact
Neurobiological Predictors of Huntington Disease, Version 2.0 (PREDICT-HD v 2.0) (more details) (study brochure) Joel Perlmutter Stacey Barton
314-362-3471
Creatine Safety, Tolerability & Efficacy in huntington’s Disease. (more details) Brad Racette Pat Deppen
362-8548

Dystonia

Study Title Principal Investigator Contact
Dystonia Coalition: Project 1: Natural History and Biorepository for Primary Dystonia. (Study Brochure) Joel Perlmutter Laura Wright
362-7148
Role of Dopamine Receptors in Primary Focal Dystonias (more details) Stacy Pratt
314-747-5916

Tourette Syndrome or Tics

Study Title Principal Investigator Contact
Testing the phasic dopamine release hypothesis in Tourette syndrome: pilot Kevin Black Emily Bihun (314) 362-2083;
bihune@npg.wustl.edu
The effects of tactile stimulation on the attentional performance of subjects with sensory hypersensitivity or Tourette syndrome: pilot Kevin Black Jackie Schechter, email:
volunteer@tourette.us
Predictive Biomarkers of Conversion to Tourette Syndrome in Children with New-Onset Tics (more details) Kevin Black Emily Bihun (314-362-2083) BihunE@npg.wustl.edu

Others

Study Title Principal Investigator Contact
Myobloc for Sialorrhea Treatment with Intraglandular Injections – Controlled and Open-Label Study. (more details) Brad Racette, MD Karen McDonell
314-747-514
Biospecimen and Clinical Data Acquisition Neurological and Psychiatric Genetics Repository (more details) Joel Perlmutter Anja Pogarcic
314-362-3483